Invitrocue

Invitrocue develops proprietary platforms using patient-derived organoids and advanced imaging analytics to support personalized oncology decision-making. Their Onco-PDO™ test grows patients’ own tumor cells in the lab to screen approved drugs, helping oncologists select optimal therapies. The company’s technologies are used by pharmaceutical companies for preclinical drug development as well as by clinicians for individualized treatment planning. Validation studies have shown that their breast cancer organoid models mimic disease heterogeneity and correlate with clinical response. They operate globally with labs in Singapore, Hong Kong, China, Germany, Spain, and Brazil.